- Home
- SRV vs EDIT Comparison
SRV vs EDIT Comparison
Compare SRV & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRV
- EDIT
- Stock Information
- Founded
- SRV 2007
- EDIT 2013
- Country
- SRV United States
- EDIT United States
- Employees
- SRV N/A
- EDIT N/A
- Industry
- SRV Finance Companies
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SRV Finance
- EDIT Health Care
- Exchange
- SRV Nasdaq
- EDIT Nasdaq
- Market Cap
- SRV 173.0M
- EDIT 156.5M
- IPO Year
- SRV N/A
- EDIT 2016
- Fundamental
- Price
- SRV $41.34
- EDIT $1.91
- Analyst Decision
- SRV
- EDIT Buy
- Analyst Count
- SRV 0
- EDIT 13
- Target Price
- SRV N/A
- EDIT $6.73
- AVG Volume (30 Days)
- SRV 33.9K
- EDIT 1.9M
- Earning Date
- SRV 01-01-0001
- EDIT 05-12-2025
- Dividend Yield
- SRV 13.38%
- EDIT N/A
- EPS Growth
- SRV N/A
- EDIT N/A
- EPS
- SRV N/A
- EDIT N/A
- Revenue
- SRV N/A
- EDIT $35,837,000.00
- Revenue This Year
- SRV N/A
- EDIT N/A
- Revenue Next Year
- SRV N/A
- EDIT N/A
- P/E Ratio
- SRV N/A
- EDIT N/A
- Revenue Growth
- SRV N/A
- EDIT N/A
- 52 Week Low
- SRV $30.73
- EDIT $0.91
- 52 Week High
- SRV $44.30
- EDIT $6.22
- Technical
- Relative Strength Index (RSI)
- SRV 59.49
- EDIT 63.55
- Support Level
- SRV $40.76
- EDIT $1.73
- Resistance Level
- SRV $41.56
- EDIT $1.98
- Average True Range (ATR)
- SRV 0.66
- EDIT 0.17
- MACD
- SRV 0.13
- EDIT 0.02
- Stochastic Oscillator
- SRV 91.15
- EDIT 87.27
About SRV NXG Cushing Midstream Energy Fund of Beneficial Interest
NXG Cushing Midstream Energy Fund is a non-diversified, closed-end management investment company with an investment objective of seeking a high after-tax total return from a combination of capital appreciation and current income. The fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in midstream energy investments.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.